The details of two rheumatoid arthritis (RA) patients with systemic sclerosis (SSc) who were administered tocilizumab, an anti-interleukin-6 receptor antibody, are reported, along with a review of the literature. Two RA patients with SSc with inadequate responses to disease-modifying antirheumatic drugs (DMARDs) were given tocilizumab 162 mg every 2 weeks for 18 months. RA disease activity was evaluated by the 28-joint disease activity score with erythrocyte sedimentation rate (DAS28-ESR) and the clinical disease activity index (CDAI). The skin condition of SSc was evaluated by pinching the skin according to the modified Rodnan total skin thickness score (mRSS). Softening of the skin and improvements of arthritis and the patient global assessment were observed during tocilizumab treatment, with reduction of not only RA disease activity, but also of the mRSS. Tocilizumab may be effective in patients with RA and SSc overlap syndrome for which conventional treatment is inadequate. Further research is needed because this report included only two patients.

中文翻译：

---

皮下注射托珠单抗治疗类风湿关节炎合并系统性硬化重叠综合征患者疗效：附2例并文献复习

报告了两名患有系统性硬化症 (SSc) 的类风湿性关节炎 (RA) 患者的详细信息，这些患者接受了抗白细胞介素 6 受体抗体托珠单抗治疗，同时对文献进行了回顾。两名患有 SSc 的 RA 患者对改善疾病的抗风湿药物 (DMARDs) 反应不足，每 2 周给予 162 mg 托珠单抗，持续 18 个月。通过红细胞沉降率 (DAS28-ESR) 和临床疾病活动指数 (CDAI) 的 28 关节疾病活动评分来评估 RA 疾病活动性。根据改良的 Rodnan 总皮肤厚度评分 (mRSS) 通过捏皮肤来评估 SSc 的皮肤状况。在托珠单抗治疗期间观察到皮肤软化和关节炎改善以及患者整体评估，不仅减少了 RA 疾病活动，还有mRSS。托珠单抗可能对常规治疗不足的 RA 和 SSc 重叠综合征患者有效。需要进一步研究，因为该报告仅包括两名患者。